Orthocell's Remplir hits 90% success rate

Orthocell managing director Paul Anderson talked with Proactive about new real-world data supporting the company’s nerve repair product, Remplir(TM), highlighting its strong clinical performance and growing commercial traction.

Anderson explained that the latest dataset demonstrates a 90% success rate across a diverse patient group, ranging from ages 14 to 82, covering multiple nerve repair interventions. He said this broader dataset provides a more robust and meaningful validation of the product’s effectiveness beyond controlled clinical trials.

The discussion also covered Remplir’s commercial positioning. The product is fully reimbursed in Australia’s private healthcare system and is competitively priced, supporting adoption among surgeons and hospitals. Orthocell has already achieved significant penetration locally, with more than 300 surgeons and 250 hospitals using the product, helping validate its clinical and commercial value.

For more insights like this, visit Proactive’s YouTube channel, give the video a like, subscribe, and enable notifications so you never miss future updates.

#Orthocell #Remplir #Biotech #MedTech #NerveRepair #ASXStocks #HealthcareInnovation #MedicalDevices #Investing #SmallCaps #USMarket #Biotechnology #HealthcareStocks #ClinicalData #StockMarket

Видео Orthocell's Remplir hits 90% success rate канала Proactive Investors